Ginkgo Bioworks is a synthetic biology platform company that programs cells to solve problems across industrial biotech, food science, pharmaceuticals, biosecurity, and other industries. The company operates two segments: Cell Engineering, providing biological R&D services and tools for customers; and Biosecurity, delivering services to identify, monitor, prevent, and mitigate biological threats. Founded in 2008 by MIT scientists including Jason Kelly, Reshma Shetty, Barry Canton, Tom Knight, and Austin Che, Ginkgo went public via SPAC merger in September 2021 on NYSE under ticker DNA.
Ginkgo Bioworks is publicly traded
This company is no longer available on our private secondary market. Shares can be traded publicly under its listed ticker.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2008
Employees
894
Total Funding
$789M
7 rounds
Last Private Valuation
$4B
Sep 19, 2019
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $789M across 7 rounds
Last updated 06-25-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| May 28, 2020 | Series E Extension (Illumina) Press release | $70M | — | Illumina |
| Sep 19, 2019 | Series E Press release | $290M | $4B | T. Rowe Price Associates |
| Dec 14, 2017 | Series D | $275M | — | General Atlantic |
Jason Kelly
Co-Founder and Chief Executive Officer
Reshma Shetty
Co-Founder, President, and Board Member
Barry Canton
Co-Founder and Chief Technology Officer
Jennifer Wipf
Chief Commercial Officer and Chief Operating Officer (as of Jan 2026)
Ginkgo Bioworks completed a SPAC merger with Soaring Eagle Capital Partners and began trading on the New York Stock Exchange under ticker DNA on September 17, 2021. The company raised $2.5 billion in gross proceeds, including $775 million in PIPE funding and approximately $858 million from the SPAC trust account.
Ginkgo Bioworks shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker to place an order.
Ginkgo Bioworks had a valuation of approximately $4B at the time of its public offering. Current market capitalization fluctuates with the share price.
Ginkgo Bioworks raised $789M across 7 disclosed funding rounds prior to its public listing.
Ginkgo Bioworks was co-founded by Jason Kelly, Reshma Shetty, and Barry Canton in 2008.
Ginkgo Bioworks is headquartered in Boston, MA, United States.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.